C

Curatis Holding
CURN

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
CHF60.45M
EV
-
Shares Outstanding
5.04M
Beta
-
Industry
-

Wall Street View

Analyst Rating
NO_OPINION
Analyst Target Price
Number of Analysts
1
P/E E
-
P/Revenue E
-

Historical 3Y Growth Rate

Revenue
-
EPS
-
Operating Cash Flow
-
Free Cash Flow
-

Forecasted 3Y Growth Rate

Revenue
-
EPS
-
Operating Cash Flow
-
Free Cash Flow
-

Margins & Returns

Gross Margin E
-
Net Profit Margin E
-
ROE E
-
ROCE
-

Dividends

DPS E
-
Payout Ratio E
-
Div. Yield E
-
DPS Last 3Y CAGR
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Curatis Holding AG

gainify

C

Curatis Holding AG

CURN

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of antiplatelet, metastatic hormone receptor-positive b...

Sector

Industry

CEO

Rutschmann, Roland

Employees

20

IPO Date

Headquarters

Weierweg 7, Liestal, Basel-Landschaft, 4410, Switzerland

📊 Stock Price & Performance

Based on current CURN analyst forecasts and market assumptions, the consensus price target for Curatis Holding (CURN) is CHF98.10 for 2027. Price targets reflect forward-looking estimates based on information available at the time and are inherently subject to change as underlying assumptions, company fundamentals, or market conditions evolve. Last updated:

💰 Financial Metrics & Reports

The current Curatis Holding (CURN) market capitalization is approximately CHF60.45M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Curatis Holding's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:03 AM Eastern Time

📅 Earnings & Dividends

Curatis Holding (CURN) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CHF0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.

📈 Analyst Information

Analyst assessments of whether Curatis Holding (CURN) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Consensus price target: CHF98.10Implied return: +497.17% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice.

Based on the latest available analyst coverage, Curatis Holding (CURN) currently carries a NO_OPINION consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice.

Like other publicly traded stocks, Curatis Holding (CURN) shares are bought and sold on stock exchanges such as SWX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Curatis Holding (CURN) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

ℹ️ Company Information

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add CURN to your watchlist.

Curatis Holding trades under the ticker symbol CURN on the SWX stock exchange. The ticker CURN is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Curatis Holding (CURN) employs approximately 20 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: January 1, 2026 at 12:03 AM Eastern Time

Curatis Holding (CURN) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Curatis Holding (CURN) stock peers based on overlapping products, services, and competitive dynamics:Moberg Pharma (MOB)Orexo (ORX)Iterum Therapeutics (ITRM)Infant Bacterial Therapeutics (IBT B)BioVersys (BIOV)Photocure (PHO)Klaria Pharma Holding AB (publ.) (KLAR)Marinomed Biotech (MARI)Enzymatica (ENZY) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Curatis Holding.

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2026 Gainify. All rights reserved.